Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Scott Randall Plotkin, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Scott Plotkin and Justin Jordan.
Connection Strength

5.693
  1. Neurofibromatoses. Hematol Oncol Clin North Am. 2022 02; 36(1):253-267.
    View in: PubMed
    Score: 0.939
  2. Benign Intracranial Tumors. Neurol Clin. 2018 08; 36(3):501-516.
    View in: PubMed
    Score: 0.750
  3. Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018 Feb; 97(5):e9717.
    View in: PubMed
    Score: 0.725
  4. Glioblastoma care in the elderly. Cancer. 2016 Jan 15; 122(2):189-97.
    View in: PubMed
    Score: 0.623
  5. Teaching NeuroImages: brain mass with hilar adenopathy: the importance of histologic diagnosis. Neurology. 2014 May 06; 82(18):e161-2.
    View in: PubMed
    Score: 0.559
  6. Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. Am J Med Genet A. 2022 Sep; 188(9):2672-2683.
    View in: PubMed
    Score: 0.245
  7. Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet J Rare Dis. 2022 02 10; 17(1):44.
    View in: PubMed
    Score: 0.240
  8. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61.
    View in: PubMed
    Score: 0.223
  9. Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 23; 7(10):e11008.
    View in: PubMed
    Score: 0.191
  10. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res. 2018 Aug 29; 18(1):668.
    View in: PubMed
    Score: 0.189
  11. Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1: Population-Based Approach. Stroke. 2016 Jan; 47(1):60-5.
    View in: PubMed
    Score: 0.156
  12. Magnetic resonance imaging observations in primary central nervous system lymphoma. JAMA Neurol. 2014 Jul 01; 71(7):918-9.
    View in: PubMed
    Score: 0.141
  13. Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis. Am J Med Genet A. 2022 08; 188(8):2413-2420.
    View in: PubMed
    Score: 0.061
  14. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022 04 14; 139(15):2306-2315.
    View in: PubMed
    Score: 0.061
  15. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S32-S41.
    View in: PubMed
    Score: 0.057
  16. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2021 Jan-Jun; 296:100157.
    View in: PubMed
    Score: 0.055
  17. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2020 Dec 09; 296:100157.
    View in: PubMed
    Score: 0.055
  18. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns. 2021 04; 104(4):808-814.
    View in: PubMed
    Score: 0.054
  19. Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics. Neurology. 2020 06 16; 94(24):e2521-e2531.
    View in: PubMed
    Score: 0.053
  20. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist. 2020 07; 25(7):e1109-e1116.
    View in: PubMed
    Score: 0.053
  21. First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. J Neurooncol. 2019 Jul; 143(3):505-513.
    View in: PubMed
    Score: 0.049
  22. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 08 02; 20(9):1185-1196.
    View in: PubMed
    Score: 0.047
  23. Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342.
    View in: PubMed
    Score: 0.045
  24. First report of factors associated with satisfaction in patients with neurofibromatosis. Am J Med Genet A. 2017 03; 173(3):671-677.
    View in: PubMed
    Score: 0.042
  25. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419.
    View in: PubMed
    Score: 0.042
  26. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015 Jul 10; 6(19):16981-97.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.